Cannabis Legalization Outcomes: What 329 Studies Found
Cannabis legalization outcomes across 329 studies included fewer possession arrests and generally more adult access and use. Youth prevalence did not rise uniformly, but pediatric exposure and acute-care signals remained important. Market and road-safety…
GLP-1 Drugs and Cervical Fusion: What Conflicting
GLP-1 cervical fusion outcomes were synthesized across 12 retrospective cohorts. Estimates differed by procedure and dataset, and the overall model showed extreme heterogeneity. The evidence does not establish a protective or harmful class-wide effect.
Cannabinoids for Mental Health and Addiction: What 200
Cannabinoids for mental health were examined across 200 randomized and observational studies. Anxiety and PTSD signals were limited by low certainty, indirectness, and heterogeneity, while depression showed no evident benefit. THC increased withdrawals…
Varenicline for Cannabis Use Disorder: What Five Studies Show
Varenicline for cannabis use disorder: A systematic review of five studies involving 299 participants found mixed efficacy and tolerability results. Only one study was rated high quality, and methods were too heterogeneous for meta-analysis. Current…
2026 Review: Cannabinoids in Managing MS Spasticity
This 2026 systematic review evaluates cannabinoids for MS spasticity, finding modest improvements with THC:CBD extracts. Despite low evidence certainty, cannabinoids may aid some patients with MS spasticity as adjunctive therapy. Careful clinical…
What Happens After Cannabis Laws Change? A Review of 176 Policy Studies
Cannabis policy and substance use evidence from 176 quasi-experimental reports shows adult cannabis use often rises after liberalization. Alcohol, tobacco, opioid, and youth outcomes varied by policy and population. The review supports targeted…
Purified CBD and Epilepsy: Insights on Nonseizure Outcomes from New Review
A recent systematic review examined highly purified cannabidiol epilepsy treatment focusing on nonseizure outcomes such as cognition, behavior, and quality of life. The evidence, mainly observational, suggests potential benefits but remains inconclusive…
Cannabis and Parkinson’s Disease: What a New Evidence Review Shows
A recent systematic review evaluated cannabis sativa Parkinsons motor symptoms and found Grade A evidence indicating no motor benefit. This review clarifies cannabis sativa's role in Parkinson's motor symptom treatment. It highlights the need for careful…
Insights on Cannabinoid Exposure in Substance Use Disorders
This 2026 review on cannabinoid exposure substance use disorders analyzes 97 studies with over 41,000 participants. It finds cannabinoids offer short-term symptom relief but lack durable efficacy for abstinence or relapse prevention. The evidence guides…
Cannabinoids in Substance Use Disorders: What a New Systematic Review Actually Found
Cannabinoids and substance use disorders were the focus of a 2026 systematic review spanning 97 studies and nearly 42,000 participants. The review found cannabinoids more often relieved short-term symptoms like craving and withdrawal than they improved…